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metabolic pathway gene expression in mice <p>In order to evaluate metabolic pathways associated with obesity, global gene-expression data were integrated with phenotypic and  genetic segregation analyses, identifying 13 metabolic pathways the genes of which are coordinately regulated in association with obesity.  Four genomic regions were found to control the coordinated expression of these pathways and novel genes potentially associated with the  identified pathways were identified.</p>
Abstract
Background: A segregating population of (C57BL/6J × DBA/2J)F2 intercross mice was studied for
obesity-related traits and for global gene expression in liver. Quantitative trait locus analyses were
applied to the subcutaneous fat-mass trait and all gene-expression data. These data were then used
to identify gene sets that are differentially perturbed in lean and obese mice.
Results: We integrated global gene-expression data with phenotypic and genetic segregation
analyses to evaluate metabolic pathways associated with obesity. Using two approaches we
identified 13 metabolic pathways whose genes are coordinately regulated in association with
obesity. Four genomic regions on chromosomes 3, 6, 16, and 19 were found to control the
coordinated expression of these pathways. Using criteria that included trait correlation, differential
gene expression, and linkage to genomic regions, we identified novel genes potentially associated
with the identified pathways.
Conclusion: This study demonstrates that genetic and gene-expression data can be integrated to
identify pathways associated with clinical traits and their underlying genetic determinants.
Background
Comprehensive high-throughput analytical techniques such
as expression microarrays have brought about a rethinking of
the possibility of understanding biology and disease at a glo-
bal ('systems biology') level [1,2]. These techniques have been
applied widely to the study of the time course of events in spe-
cific cells or organisms, and to different conditions for a given
cell type or organism. More recently, there has been an appre-
ciation of the possibility of using naturally occurring genetic
variation as a means of generating perturbations, with the
advantage of allowing identification of the individual genetic
factors affecting the trait of interest in the segregating popu-
lation [3]. We and others have begun to apply this approach
to various model organisms where tracking of genetic segre-
gation is feasible [4-10].
Traditional quantitative trait locus (QTL) analyses of complex
traits in model organisms have focused on the identification
of specific causative genes that differ between the originating
strains and that are directly responsible for the variation in
trait expression [11]. The availability of genome-wide expres-
sion data (or proteomic, metabolomic, or other such global
analyses) to complement the measurements of the physio-
logic trait opens new opportunities for identifying specific
Published: 1 July 2005
Genome Biology 2005, 6:R59 (doi:10.1186/gb-2005-6-7-r59)
Received: 8 December 2004
Revised: 1 February 2005
Accepted: 8 June 2005
The electronic version of this article is the complete one and can be 
found online at http://genomebiology.com/2005/6/7/R59R59.2 Genome Biology 2005,     Volume 6, Issue 7, Article R59       Ghazalpour et al. http://genomebiology.com/2005/6/7/R59
Genome Biology 2005, 6:R59
biologic processes and genes that are involved in trait expres-
sion. As well as providing a means of evaluating many of the
potential candidate genes responsible for a specific QTL, such
data allow the identification of pathways and genes that have
a role in the expression of the phenotype, either as intermedi-
ate players between the causative gene and the phenotype, or
as being responsive to the trait [12].
We have been interested in using these approaches in mice to
understand the pathogenesis of obesity and vascular disease,
among other related conditions [6,13]. Metabolic dysregula-
tion has been recognized to be an important element in the
pathogenesis of these poorly understood conditions. An
important dataset for these purposes is the (C57BL/6 × DBA/
2)F2 (BxD) intercross presented in Schadt et al. [6]. This set
comprises the microarray data from the liver of BxD F2
female mice fed an atherogenic diet for 4 months beginning at
12 months of age. In this study, we integrate the global gene-
expression data with phenotypic and genetic segregation
analyses to evaluate metabolic pathways associated with
obesity in the BxD set. We show that this approach allows
identification of specific pathways whose gene expression is
coordinately regulated in association with obesity, defined
genomic regulatory loci controlling the expression of these
genes, and novel genes that are functionally associated with
the identified pathways.
Results
Identification of gene sets/pathways associated with 
the subcutaneous fat pad mass trait
To identify functionally related gene sets that are differen-
tially perturbed in lean and obese mice of the BXD cross, two
methods were applied: gene set enrichment analysis (GSEA)
[14] and over-representation analysis using Fisher's exact
test. For both of these, we began by selecting a set of 4,670
genes that were differentially expressed in the liver, filtered as
described in the Materials and methods section. In both anal-
yses, we used the same 378 gene sets compiled mainly from
the Kyoto Encyclopedia of Genes and Genomes (KEGG) [15]
and Biocarta [16] sources. GSEA was implemented as previ-
ously described [14]. To apply GSEA, the 4,670 filtered genes
were ranked on the basis of significance of differential expres-
sion between the obese and lean groups of mice (identified as
those mice in the upper and lower 15th percentiles for the
subcutaneous fat-pad mass trait, respectively). The Kol-
mogorov-Smirnov (KS) test was then applied as described in
[14] to test the null hypothesis that members of a given gene
set are randomly ranked. This procedure generates an enrich-
ment score (ES) for each gene set. The significance of the ES
statistic was determined empirically by performing the anal-
ysis after random permutation of the grouping assignment of
the mice, with the probability of falsely rejecting the null
hypothesis determined by repeating the permutation proce-
dure 1,000 times. This established that ESs greater than 114
allowed rejection of the null hypothesis at a level of 0.05.
Using this empirically determined threshold for the ES statis-
tic, we identified 13 gene sets that were differentially regu-
lated between mice that have high and low subcutaneous fat-
pad mass (Figure 1).
As a second approach, we used an analysis of over-represen-
tation of gene set members by applying the Fisher's exact test,
as implemented by the Expression Analysis Systematic
Explorer (EASE) software [17]. The results are shown in Table
1 and are comparable to those of the GSEA analysis. Ten of the
13 pathways identified as significantly differentially
expressed using the GSEA approach were also identified as
significantly differentially expressed by the EASE analysis
after application of the Hochberg adjustment for multiple
comparisons. Two of the other three gene sets identified by
GSEA were the 12th- and 13th-ranked sets by the EASE anal-
ysis. One gene set (tetrachloroethene degradation) was iden-
tified as significant by the Fisher's exact analysis but not by
GSEA.
Relationships among pathway sets, gene expression, 
and the fat-mass phenotype
The gene sets identified as being differentially regulated
between obese and lean mice represented metabolic path-
ways involved in energy and lipid metabolism. Note that
genes can contribute to multiple pathways, as different path-
ways can be biologically interrelated. The majority of path-
ways feed into the tricarboxylic acid (TCA) cycle (Figure 2).
The aggregate gene set from all 13 fat-mass-associated path-
ways comprises 170 genes, 150 of which were represented on
the array. An examination of the correlation between relative
gene-expression levels and the fat-mass trait showed that 68
of the 150 genes (45%) in the aggregate set were correlated at
p < 0.05 (not corrected for multiple comparisons). A large
majority of these genes (61/68) showed a significant positive
correlation (that is, they were upregulated in obese compared
with lean mice), with relatively few being negatively corre-
lated (10%). Within individual pathway sets, between 42%
and 63% of the genes were significantly correlated. The
majority of correlated genes in a given set were always posi-
tively correlated. The magnitude of the correlations was com-
parable across the 13 pathways.
Identification of genetic loci controlling differentially 
regulated pathway genes
We hypothesized that the composite set of pathways repre-
sented a functionally interrelated gene set responding to com-
mon genetic controls (referred to subsequently as the obesity-
associated pathway set). Two approaches were taken to test
for such common genetic controls. The first was to test for the
enrichment of pathway gene-expression quantitative trait loci
(eQTLs) along genomic intervals, and the second was princi-
pal component analysis (PCA) of the gene set, followed by
QTL mapping of the derived principal components.http://genomebiology.com/2005/6/7/R59 Genome Biology 2005,     Volume 6, Issue 7, Article R59       Ghazalpour et al. R59.3
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When eQTLs for the 4,670 most differentially expressed
genes were mapped we found that there were 15,262 eQTLs
with log10 of the odds (LOD) score greater than 2.0. Of these
eQTLs, 278 corresponded to 77 genes represented in the 13
differentially regulated pathways identified above by the
GSEA procedure. To examine whether there was an enrich-
ment of pathway gene eQTLs among the eQTLs of the 4,670
most differentially expressed genes along the genomic inter-
vals, we first divided the genome into sequential overlapping
20 centimorgan (cM) intervals, beginning a new interval
every 10 cM. We then counted how many of the eQTLs overall
for the 4,670 differentially expressed genes and how many of
the eQTLs specific for the 77 pathway genes defined above
mapped to each interval. In general, assuming under the null
hypothesis that the genomic location of genes influencing the
transcript levels of other genes in common pathways is inde-
pendent, the expected number of pathway gene eQTLs map-
ping to each interval is (M/B) × K where B is 4,670, M is the
subset from the 4,670 genes that have eQTLs mapping to the
interval, and K is 77. To compute the statistics we applied
Fisher's exact test. The p-values obtained for the statistics are
shown in Table 2. For these calculations we applied a total of
180 tests overall, corresponding to 180 bins that comprise the
entire genome. The significance levels of these tests are
reported in Table 2 under 'adjusted p-value', which reflects
the p-values after applying the Bonferroni correction criteria
(multiplying the p-values by 180, the number of tests).
After correcting for multiple comparisons, significant over-
representation of pathway gene eQTLs was obtained for four
loci located on chromosomes 3 (80-100 cM), 6 (30-50 cM), 16
(1-20 cM), and 19 (20-50 cM) (Figure 3, Table 2). All path-
ways were represented at each locus and there were no appar-
ent subgroups associated with some loci and not others. We
Significantly differentially regulated pathways identified by GSEA analysis Figure 1
Significantly differentially regulated pathways identified by GSEA analysis. The histogram represents the frequency distribution of maximum ES scores 
obtained with GSEA analysis after 1,000 random permutations of class assignment (obese or lean). The location of the gray arrow corresponds to p = 0.05 
(ES = 114.0), and pathways with scores greater than this (indicated by the black arrows) are listed.
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also found that about half of the genes had eQTLs at two or
more of the four loci.
An alternative approach that has been proposed to test for
coordinated regulation of the genes in individual pathways is
PCA [7,18]. PCA was applied using the gene sets from all 13
significant pathways identified by GSEA, and the aggregate
set of 150 genes comprising these 13 pathways. The mean log
ratios of the gene expression for all genes within these path-
ways across the F2 mice were subject to the analysis. Principal
components (PC) that explained more than 5% of the vari-
ance of transcript levels of the genes within each pathway
were then mapped as quantitative traits. Only three compo-
nents showed significant LOD scores (> 4.3). These included
the third PC for fatty acid metabolism-1 pathway (LOD 21.4),
the fourth PC for γ -hexachlorocyclohexane degradation (LOD
14.8), and the fourth PC of the tryptophan degradation path-
way (LOD 8.1). All these linkages mapped to the same locus at
36 cM on chromosome 19. The percentage of variance
explained by each of these PCs was 8%, 8%, and 7%,
respectively. QTL analyses of individual genes in the fatty-
acid metabolism and γ -hexachlorocyclohexane degradation
pathway revealed the presence of two cis-eQTLs at the chro-
mosome 19 locus with very significant LOD scores: Cyp2c40
(LOD = 20.7) and Cyp2c39 (LOD = 12.4). To see whether
these two genes were the major contributors to mapping of
the PCs to chromosome 19, we carried out the analysis with-
out these two genes for each of the pathways separately. The
resulting components showed no evidence of significant link-
age genome-wide.
Relationship of pathway regulatory regions to the 
subcutaneous fat-mass trait
The loci identified above are genomic regions with apparent
regulatory control of pathway genes that are differentially
perturbed between obese and lean mice. The locus allele
effects on the subcutaneous fat-mass trait, using the nearest
markers at each locus, are shown in Figure 4. The loci on
chromosomes 6 and 19, which involve the greatest number of
pathway genes, showed the strongest effects and in fact had
been identified as being linked to adiposity in previous stud-
ies [6,19]. Consistent allele effects were observed among the
subset of genes from the aggregate pathway set that had
eQTLs at both the chromosome 6 and chromosome 19 loci
(that is, a gene that showed a positive correlation with fat
mass showed greater expression with the B6 versus DBA
homozygous mice at the chromosome 19 locus, and the
reverse at the chromosome 6 locus).
Use of expression data for prioritization of candidate 
gene selection at the chromosome 19 locus
The chromosome 19 locus had the greatest impact on the
expression of pathway set gene expression, and it was of
interest to identify the candidate responsible genes for fur-
ther study. For candidate genes regulated at the level of
expression (that is, the gene controls its own transcript abun-
dance), an eQTL will be present proximal to the physical loca-
tion of the gene; we have referred to such an eQTL as a cis-
eQTL [6]. Cis-eQTLs were defined as any gene with eQTLs
mapping to 20 Mb (approximately 10 cM) on either side of the
gene's physical location. This definition reflects the relative
accuracy of the 13 cM dense BxD QTL map. The decision to
Relationship of the 13 differentially regulated pathways identified by GSEA Figure 2
Relationship of the 13 differentially regulated pathways identified by GSEA. 
Nine pathways were related via the tricarboxylic acid (TCA) cycle and 
three other pathways are linked through cholesterol metabolism. These 
pathways contain a total of 170 genes, some of which are present in 
multiple pathways.
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Identification of genomic regions controlling obesity-associated pathway  gene expression Figure 3
Identification of genomic regions controlling obesity-associated pathway 
gene expression. The x-axis represents sequential 10-cM intervals across 
the genome and the y-axis represents the negative log10 of adjusted 
Fisher's exact test p-value for enrichment of eQTLs in overlapping 20-cM 
bins. The dashed line corresponds to the p-value 0.05 after correcting for 
multiple comparison. The four significantly enriched regions on 
chromosomes 3, 6, 16, and 19 are indicated by arrows.
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choose such a definition for cis-eQTLs is supported by the
work of Doss et al. [20], who showed that this definition is
reasonable by validating the cis nature of such defined eQTLs
and by showing the extreme bias in the mapping of these cis
eQTLs to regions which are not identical by descent between
the B6 and DBA strains of mice.
We identified genes with significant cis-acting eQTL (LOD
score > 4.3) that map to chromosome 19 between 20 and 50
cM, and determined the genomic location of each gene using
the University of California Santa Cruz (UCSC) Genome
Browser (build 33, mm5, May 2004). Of 249 eQTLs mapping
to the chromosome 19 locus, 19 overlapped the physical
location of their respective gene (Table 3), thus establishing
them as primary candidate genes. Of these, eight were signif-
icantly correlated with the fat-mass trait, making them partic-
ularly attractive candidates.
Integration of trait, expression, and mapping data to 
identify novel genes potentially related to the obesity-
associated gene set
The above analyses were restricted to the genes that had been
assigned to gene sets in the starting databases such as KEGG.
To identify novel genes that may belong to the same aggregate
group of obesity-associated pathway genes, we filtered the
4,670 differentially regulated genes first for correlation with
the fat-mass trait at p < 0.05 (uncorrected, corresponding to
a correlation coefficient of approximately 0.25) and subse-
quently for the presence of eQTLs falling within the identified
regulatory regions for both chromosome 6 (30 to 50 cM inter-
val) and 19 (20 to 50 cM interval). A total of 117 genes were
identified that were not members of one of the 13 obesity-
associated pathways. These include 20 genes with defined
relationships to the starting pathways (based on published
literature), but also 28 expressed sequence tags (ESTs) with
Table 1
Top 13 differentially regulated pathways identified by EASE analysis ranked by their corresponding p-values
Gene category p-value Adjusted p-value
Fatty-acid metabolism 6.91 E-08 1.48 E-05
Tryptophan metabolism 3.72 E-06 2.94 E-04
Butanoate metabolism 4.12 E-06 2.94 E-04
Glycerolipid metabolism 7.45 E-06 3.99 E-04
Valine, leucine, isoleucine degradation 4.22 E-05 1.60 E-03
Gamma-hexachlorocyclohexane degradation 4.48 E-05 1.60 E-03
Beta-alanine metabolism 6.10 E-05 1.86 E-03
Bile acid biosynthesis 1.54 E-04 4.13 E-03
Ascorbate and aldarate metabolism 1.54 E-03 3.33 E-02
Tetrachloroethene degradation 1.56 E-03 3.33 E-02
Androgen and estrogen metabolism 1.87 E-03 3.64 E-02
Pyruvate metabolism 3.72 E-03 7.56 E-01
Propanoate metabolism 6.12 E-03 9.93 E-01
Table 2
Chromosomal loci with significant enrichment for obesity-associated pathway gene eQTLs relative to eQTLs of all 4,670 most differen-
tially expressed genes
Chromosome (cM) Total number of genes 
with eQTL
Expected number of 
pathway genes with eQTL
Observed number of 
pathway genes with eQTL
p-value Adjusted p-value
3 (80-100) 25 1 9 9.24 E-11 1.68 E-08
6 (30-50) 836 14 28 8.05 E-05 1.47 E-02
16 (0-20) 431 7 21 3.44 E-06 6.27 E-04
19 (20-40) 891 15 38 1.45 E-09 2.63 E-07
19 (30-50) 709 12 31 6.77 E-08 1.23 E-05R59.6 Genome Biology 2005,     Volume 6, Issue 7, Article R59       Ghazalpour et al. http://genomebiology.com/2005/6/7/R59
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no functional annotation. A complete list is provided in Addi-
tional data file 1.
Discussion
This study shows that the incorporation of genome-wide
gene-expression data with traditional phenotypic trait data in
a mouse intercross population enables the identification of
regulated metabolic pathways and the genomic regions that
control the expression of the constituent pathway genes. In
contrast to studies with genetically altered mice, we have
studied a heterogeneous population where the genetic varia-
tions leading to the phenotypes and the changes in gene
expression are all naturally occurring. In this work, we iden-
tified metabolic pathway gene sets with altered gene expres-
sion in association with the subcutaneous fat-pad mass trait,
but the concept is applicable to other phenotypic traits where
the target organ examined would be expected to show
changes in relevant pathway gene expression. While gene-
expression changes are not sufficient to imply actual metabo-
lite flux through a pathway [21], changes in gene expression
are likely to reflect pathway involvement in a given condition.
Two approaches were used to identify gene sets whose tran-
scripts were altered in association with the fat-mass trait: the
GSEA method and Fisher's exact test. These yielded compara-
ble results, although the GSEA appeared to be more sensitive.
Central to both is the availability or construction of prede-
fined gene sets to test. We used two primary sources, the
KEGG database, composed primarily of traditional metabolic
pathways, and the Biocarta database, composed of gene sets
of varying type. The total number of genes represented in
these was relatively low (just under 2,000). There are certain
to be biologically important gene sets as yet unrecognized, as
well as currently uncategorized genes that belong in the exist-
ing sets. Our approach allows tentative functional assignment
Homozygous allele effects on fat-pad mass of mice at the four loci identified to regulate obesity associated pathway gene members Figure 4
Homozygous allele effects on fat-pad mass of mice at the four loci identified to regulate obesity associated pathway gene members. (a) Chromosome 3 
locus (peak marker at D3Mit86); (b) chromosome 6 locus (peak marker at D6Mit149); (c) chromosome 16 locus (peak marker at D16Mit100), and (d) 
chromosome 19 locus (peak marker at D19Mit63). B6, C57BL/6J; DBA, DBA/2J. *p-value < 0.05 calculated using two-sample t-test.
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to such uncategorized genes when they share properties of
correlation of expression levels with the phenotypic trait and
co-localization of eQTL with the trait QTL.
Consistent with an obesity trait, the gene sets identified were
of pathways directly or indirectly related to energy metabo-
lism. Within any given pathway, only about half of the genes
showed a correlation between transcript levels and fat mass,
consistent with the concept that regulation of a metabolic
pathway requires the control of only selected elements rather
than all constituents. It is of interest that the pathways are at
least loosely interconnected, and several of the genes exam-
ined have been shown to influence adipose tissue mass in
other studies. For example, of the total of 150 pathway genes
represented on the microarrays, the gene with the highest dif-
ferential expression between obese and lean mice was amine
oxidase copper-containing 3 (Aoc3) (12.5-fold change in
expression level). This observation is consistent with the
study in which overexpression of human AOC3  in mice
resulted in an increase in weight and subcutaneous white adi-
pose tissue when the animals were fed an atherogenic diet for
15 weeks [22]. Ten of the 13 pathways are connected through
the generation of products involved in the TCA cycle (Figure
2). The other three pathways (bile acid biosynthesis, andro-
gen/estrogen metabolism, and γ -hexachlorocyclohexane deg-
radation) are involved in cholesterol metabolism.
Coordinated control of cholesterol and fatty-acid synthesis
has been recognized for some time [23]. The production of
estrogen and androgen requires cholesterol as a precursor
and the activity of the cytochrome P450 family, members of
which were significantly upregulated in the obese F2 mice. In
the bile acid pathway, cholesterol serves as a substrate that is
converted to bile acids through the activation of 7-α -hydrox-
ylase, the transcript for which is also significantly elevated in
obese mice. Lastly, studies show that γ -hexachlorocyclohex-
ane administration has been shown to increase serum choles-
terol and very low-density lipoprotein (VLDL) levels [24].
Several genes occur multiple times in these 13 pathways (for
example, the aldehyde dehydrogenase gene family (Aldh1a1,
Aldh2, and Aldh3a2)). These enzymes are involved in the
generation of acetate, which can be converted to acetyl CoA.
The family is also involved in ascorbate/aldarate metabolism,
valine, leucine, and isoleucine degradation, propanoate
metabolism, fatty-acid metabolism, glycerolipid metabolism,
β -alanine metabolism, bile acid biosynthesis, and pyruvate
metabolism pathways (eight out of the 13 pathways). The
increased expression of the aldehyde dehydrogenases such as
Aldh3a2 in mice with higher subcutaneous fat-pad mass is
consistent with recent studies that correlate hyperinsuline-
mia with increased hepatic expression of Aldh3a2 [25].
We were able to identify specific genomic regions on chromo-
somes 3, 6, 16, and 19 that regulated these pathways. Gene
transcript levels are themselves quantitative traits for which
genetic control regions can be identified by QTL analysis
(eQTLs), just as for a traditional physiologic trait [4-6,26].
Table 3
Nineteen candidate genes with cis-eQTL in chromosome 19 locus
cis-QTL gene symbol Physical location of the gene (Mb) Estimated physical location of the eQTL (Mb) Correlation with subcutaneous fat mass
RIKEN cDNA 9530025L08 29.5 48.6 -0.29*
Cyp2c40† 39.1 40.6 0.24
Col17a1 47.0 40.6 -0.25*
Scd2 43.6 40.6 -0.19
Slk 46.9 41.8 -0.07
Cyp2c37 39.3 37.0 0.32*
Cyp2c39† 38.8 40.6 0.03
Gsto1 47.2 41.8 0.26*
Rnf134 46.4 48.6 0.05
Cutc 43.1 39.4 0.25*
Cpn1 43.3 39.4 0.28*
Cnnm1 42.8 46.2 0.27*
Acsl5 54.6 37.0 0.30*
RIKEN cDNA 1810018P12 32.0 35.7 0.24
Pik3ap1 40.6 39.4 -0.07
RIKEN cDNA 0610010D20 41.4 41.8 0.10
RIKEN cDNA 4833409A17 42.1 40.6 -0.21
RIKEN cDNA 4930538D17 45.7 38.2 -0.22
RIKEN cDNA 5730455O13 37.4 40.6 0.14
*Significant correlation of transcript levels with subcutaneous fat mass (p < 0.05). †The two genes that solely contributed to the significant LOD score 
of the fatty-acid metabolism and γ -hexachlorocyclohexane degredation principal components to chromosome 19 (see text for details).R59.8 Genome Biology 2005,     Volume 6, Issue 7, Article R59       Ghazalpour et al. http://genomebiology.com/2005/6/7/R59
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Loci that coordinately regulate pathway genes were identified
by analyzing for over-representation of identified pathway-
associated gene eQTLs among eQTLs of the set of most differ-
entially expressed genes in a given genomic region. A possible
criticism of this approach is the use of eQTLs with low LOD
scores. While a given eQTL with a low LOD score cannot be
considered significant in the genome-wide context on its own,
the co-localization of multiple related eQTLs with LOD scores
that may not meet the genome-wide significance criteria is
highly unlikely to have occurred by chance, as we show in
Table 2. It is unlikely that such eQTL clustering results from
correlated traits linking to a particular marker by chance,
given that the percent variation explained by any such marker
is modest (typically less than 10%) and given that the correla-
tion between traits is also modest (typically explaining less
than 30% of the variation between the traits). Therefore,
because the covariance between the two traits is small, it is
unlikely that the covariance between the two traits captures
the by-chance covariance between the traits and marker. The
other approach that we used to identify pathway regulatory
loci - PCA - proved less useful. When used on random or less
correlated groups of genes, PCA spreads the variance compo-
nents of the dataset over several different component vectors,
thereby diluting the very signal one is trying to capture. Other
techniques used for the decomposition of multivariate data
such as non-negative matrix factorization [27] are being
explored and may offer a more effective approach for this type
of analysis.
The loci on chromosomes 6 and 19 had the greatest number
of eQTLs, and were the two loci identified in previous studies
to be significantly linked with the subcutaneous fat-mass
trait. It is of interest that the most significant locus control-
ling this fat-mass trait is located on distal chromosome 2 [19],
which was not represented among the loci we identified here.
In the analysis reported in Schadt et al. [6], the loci on chro-
mosomes 2 and 19 were associated with distinct subsets of
mice, identified by differing expression profiles of the most
differentially regulated genes. The gene sets we identified
were associated with the chromosome 19 locus (and others)
but not the chromosome 2 locus. There are several possible
explanations (not mutually exclusive). One is that the respon-
sible 'pathways' or gene sets involved with the chromosome 2
locus are not represented in our sets. A second is that too few
genes of an associated pathway are differentially regulated to
detect over-representation. A third is that the associated
pathways primarily involve tissues that were not arrayed.
That is, because only liver expression data were available,
expression differences in other relevant tissues such as adi-
pose, muscle, brain, or gut could be primarily related to the
chromosome 2 QTL, but were not detected as these tissues
were not examined.
We show that there are hotspots of eQTL activity for pathway
gene members along the genome. One explanation for the
presence of these hotspots is the presence of a major regulator
gene within each locus that coordinately regulates obesity-
related pathways. Alternatively, these loci may contain sev-
eral such regulators that are closely linked. It is well known
that clusters of duplicated genes with related functions occur
commonly in the genome. Other clusters with diverse genes
but related functions, such as the H-2 locus, are also known.
Yet another possible explanation is that the genes with eQTL
mapping to a common hotspot are in linkage disequilibrium
(LD). Two or more genes that differ genetically between the
two strains and that are in LD will show correlated expression
levels [20]. This spurious correlation could lead to a more
convoluted trans-eQTL hotspot for these genes which is more
difficult to interpret [20]. We determined whether this situa-
tion might be occurring in our data and saw that in the 77
active pathway genes only 13 have cis-eQTLs for which there
is a minimal clustering of physical location (data not shown).
On this basis we conclude that LD is unlikely to explain the
hotspots identified in this study.
An approach to prioritizing candidate genes using eQTL
information is presented for the chromosome 19 locus. This
uses the concept that for genes regulated at the level of
transcription, cis-acting regulation can be identified by the
coincidence of an eQTL for a gene and its physical location.
We have experimentally verified that the majority of such
putative cis-eQTLs are real [20]. This approach relies, how-
ever, on variations affecting transcript levels and will miss
candidate genes with variations affecting protein function or
post-transcriptional modification, as well as variants associ-
ated with alternative splicing. In addition, the list of candi-
date genes is limited to genes represented on the microarray
chip.
Conclusion
In conclusion, this study presents one approach for using
gene-expression microarray data in conjunction with genetic
segregation to identify metabolic pathways that are altered in
association with obesity, and to identify specific genomic
regions that exert regulatory control over these pathways.
These findings contribute, along with other approaches
developing genetic regulatory networks [12], to the ultimate
goal of understanding disease pathophysiology at the systems
biology level.
Materials and methods
Animals, tissue collection, and gene-expression 
profiling
This study, along with others previously reported [6,19,28],
was based on data originating from an F2 intercross carried
out between mouse strains C57BL/6J and DBA/2J. This
intercross encompassed a two-phase study as described in
Colinayo et al. [28], using 142 female F2 mice with genome-
wide genotyping initially, followed by an additional 144
female mice to confirm specific QTLs (with genotyping lim-http://genomebiology.com/2005/6/7/R59 Genome Biology 2005,     Volume 6, Issue 7, Article R59       Ghazalpour et al. R59.9
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ited to selected loci). Subsequently, genome-wide expression
microarray analyses were obtained on portions of stored liver
samples; 111 of these were from the initial 142 mouse set that
was reported by Schadt et al. [6], and an additional 44 were
from a second set that lacked genome-wide genotype data.
All F2 progeny were fed a chow diet until 12 months of age
and then put on a high-fat high-cholesterol atherogenic diet
containing 0.5% cholic acid for 4 months (diet 90221; Harlan
Teklad). At 16 months of age these mice were euthanized and
liver and other organs were removed and frozen at -70°C for
subsequent RNA and DNA extraction. Body weight was deter-
mined before organ removal and adipose tissue depots were
removed and weighed for a subset of 96 animals in the phase
1 group.
RNA extraction and expression microarray profiling were
carried out as described using a custom ink-jet microarray
(Agilent Technologies) containing 23,574 60mer oligonucle-
otide non-control probes for profiling gene expression in liver
of the F2 mice [6]. Other tissues were not available for analy-
sis. The microarray data discussed in this publication have
been deposited in the Gene Expression Omnibus [29] of the
National Center for Biotechnology Information (NCBI) and
are accessible through GEO Series accession number
[GSE:2008]. The genotype and the phenotype of F2 mice are
given in Additional data file 2. Overall, 155 F2 mice had liver
array data, 111 had both array and genome-wide genotype
information, and 69 had array, genotype, and fat-mass trait
data available.
Linkage analysis
QTL analysis was performed using mean log10 expression
ratio values (averaged over fluor-reverse pairs) as quantita-
tive traits for the 111 mice that were part of the phase 1 group
described above. The linkage map was constructed using mic-
rosatellite markers at an average density of 13 cM using Map-
Manager QTX version 0.30 and QTL Cartographer version
2.0 [30-32]. For each trait, the LOD score was calculated at 1
cM intervals using standard interval mapping.
Gene set and pathway assembly
A total of 378 gene sets were developed for gene set enrich-
ment analysis (GSEA). Gene sets (118) representing meta-
bolic pathways were obtained from KEGG [15,33,34]. Ten
gene sets comprising genes that are highly correlated across
4 6  t i s s u e s  i n  m i c e  w e r e  s e l e c t e d  [ 3 5 ] .  T h e s e  d a t a  w e r e
obtained using the SOURCE database [36,37]. Seven path-
ways were manually curated from the published literature for
genes involved in insulin signaling. Two hundred and forty-
four gene sets were obtained by querying all the pathways
available at Biocarta [16]. The latter set comprises both sign-
aling and metabolic pathways submitted to the Biocarta
server by independent scientists. Gene sets composed of more
than 50 members were divided into smaller sets to avoid bias
related to gene set size in the GSEA analysis [38].
Microarray data filtering and ranking
A subset of genes represented on the microarray were
selected on the basis of differential expression across all the
155 mice arrayed, irrespective of phenotype. This was done to
ensure a starting gene set that was active and differentially
expressed in liver among mice. To filter for these genes, the
expression ratio and the corresponding p-value for differen-
tial expression (compared to the control pool) for each gene
were calculated as described [6,39]. Genes with p-values of
0.05 or less in 10 or more F2 mice were defined as differen-
tially expressed, which yielded a set of 4,670 genes. To study
gene subsets (within these 4,670 genes) that are associated
with obesity, the mice comprising the upper and lower 15th
percentiles of the subcutaneous fat-pad mass trait were
selected. The average and standard deviation of the mean log
ratio of expression of each differentially expressed gene for
these two groups of mice were calculated and used for the
GSEA and the Fisher's exact test analyses described below.
Gene set enrichment analysis
Gene sets that are differentially regulated in relation to the
subcutaneous fat-pad mass trait were identified using the
GSEA method as described in [14]. The groups of mice ana-
lyzed were obese and lean F2 mice as defined above. To calcu-
late the significance of the enrichment score (ES) assigned to
each pathway, class labels of lean and obese mice were
randomly permuted and ESs were recalculated 1,000 times.
The cutoff for significance of ESs in the original analysis was
defined as the score above the 50th highest score calculated in
the permutation, corresponding to an empirical p-value of
0.05.
Fisher's exact test analysis
The test subset was composed of transcripts identified as
being the 20% most differentially regulated between obese
and lean groups of mice. Fisher's exact test was applied as
implemented in the Expression Analysis Systemic Explorer
(EASE) program [17], downloaded from the Database for
Annotation, Visualization, and Integrated Discovery
(DAVID) [40,41]. The pathway set we compiled was incorpo-
rated as a file into the program for use in the analysis
(LocusLink and pathway identifier for each gene associated
with each pathway). Genes identified as being differentially
regulated as described above, but not belonging to an identi-
fied pathway or gene set were included with a designation
'unclassified', so that the EASE program would perform the
Fisher's exact analysis using the full set of differentially regu-
lated genes, rather than just those associated with an identi-
fied pathway or gene set. The set of all analyzed transcripts on
the array for which unique LocusLink identifiers were availa-
ble was entered as the population set in the analysis, although
in the EASE analysis this set is limited to the genes that are
represented in the pathway being evaluated.R59.10 Genome Biology 2005,     Volume 6, Issue 7, Article R59       Ghazalpour et al. http://genomebiology.com/2005/6/7/R59
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cis-eQTL identification
We adopted the same cis-eQTL definition as described in
[20]. An eQTL was defined as a proximal or cis-eQTL when
the eQTL mapped within a 20 megabase (Mb) window on
either side of the physical location of the gene. This corre-
sponds to an approximately 20 cM segment of the genetic
map, which is the approximate level of accuracy for a QTL
given a genetic map with an average inter-marker distance of
13 cM. The following approach was taken to equate cM loca-
tions on the genetic map (constructed by the QTL software for
this specific cross) with the Mb locations of the physical map,
in order to be able to define eQTL as cis or trans. The physical
location of the gene was obtained from the UCSC Genome
Browser (build 33, mm5, May 2004). To map the genetic map
location of the eQTL to the approximate equivalent location
on the physical map, the physical map locations of the micro-
satellite markers immediately adjacent (proximal and distal)
to the eQTL were identified from the UCSC genome browser
(build 33, mm5, May 2004). Then the Mb 'location' of the
eQTL was determined by interpolation based on the relative
location of the eQTL between the markers on the genetic map.
Principal components analysis
PCA was performed as implemented in the R statistical soft-
ware version 1.8.1 [42] using the 'base' package. The principal
components and eQTL were mapped using the standard
interval mapping procedures implemented in MapManager
QTX version 0.30 and composite interval mapping imple-
mented in the Windows QTL Cartographer software version
2.0 [30-32].
Additional data files
The following additional data are available with the online
version of this paper. Additional data file 1 is a table listing
genes that were not included in any tested gene set but are sig-
nificantly correlated with subcutaneous fat mass and have
eQTLs on chromosomes 6 and 19 (ordered alphabetically by
gene name). Additional data file 2 is a table listing genotype
and fat-mass trait data for the mice used in this study.
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